These inherent pharmacokinetic and pathophysiological gaps demand careful human-equivalent dosing and long-term translational studies before antioxidant benefits can be claimed (Sharma and McNeill, 2009
Injectable GLP-1 formulations are largely unaffected by food, as they are absorbed directly from subcutaneous tissue into the bloodstream
The most common side effects include: Nausea One of the most frequently reported side effects Often mild to moderate Usually improves over time or with dose adjustment Diarrhea Loose stools or increased bowel movements Staying hydrated is important Decreased Appetite May contribute to weight loss Can sometimes lead to eating too littlemonitor your calorie and nutrient intake Vomiting Less common than nausea, but can occur especially at higher doses Talk to your provider if persistent or severe Constipation May occur as digestion slows down Drinking water and adding fiber can help Indigestion or Heartburn Also known as dyspepsia Eating smaller meals and avoiding spicy foods may reduce discomfort Fatigue Some users report feeling tired, especially during the first few weeks Less Common but Serious Side Effects Although rare, some patients may experience more serious side effects
Analysts predict continued double-digit growth for the GLP-1/metabolic disease market, driven by global obesity trends and more indications
Diabetes Care 48:S181S206 Maddaloni E, Tuccinardi D (2024) Obesity in type 1 diabetes: an overlooked immune-metabolic issue
For laboratory research use only not for human or veterinary use
